Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP902 in Mild Cognitive Impairment Due to Alzheimer's Disease
NCT07579884Phase 2Recruiting
- Sponsor
- Risen Pharma
- Start
- Jul 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RP902 in Mild Cognitive Impairment (MCI), sponsored by Risen Pharma. Started Jul 2026; status: recruiting.
02
Drugs
RP902
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07579884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579884.